

Apokyn® (apomorphine) - First-time generic

- <u>TruPharma launched</u> Sage Chemicals' <u>AP-rated</u> generic version of MDD US Operations' <u>Apokyn</u> (apomorphine) drug cartridges.
 - Patients starting treatment with <u>generic apomorphine injection</u> will need to separately obtain the Apokyn Pen. This generic approval is for the drug cartridges only, which are compatible for use with the Apokyn Pen, the brand-name pen injector.
 - Sage Chemicals' generic Apokyn is eligible for 180 days of Competitive Generic Therapy exclusivity.
- Apokyn is approved for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced Parkinson's disease.
- TruPharma will supply generic Apokyn drug cartridges; however, in limited quantities due to current manufacturing and supply chain constraints.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.